FLNA FILANA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, FILANA THERAPEUTICS INC reported revenue of n/a, net income of −$8.60M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
FLNA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$95.4M, net income −$91.0M (margin n/a), EPS −$1.88
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$141M, net income −$24.3M (margin n/a), EPS −$1.46
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$106M, net income −$97.2M (margin n/a), EPS −$2.32
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$80.0M, net income −$76.2M (margin n/a), EPS −$1.90
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$32.9M, net income −$32.4M (margin n/a), EPS −$0.82
FLNA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$8.60M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.3M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$12.5M, EPS −$0.26
- Quarter ended Sep 30, 2025: revenue n/a, net income −$10.8M, EPS −$0.22
- Quarter ended Jun 30, 2025: revenue n/a, net income −$44.2M, EPS −$0.92
- Quarter ended Mar 31, 2025: revenue n/a, net income −$23.4M, EPS −$0.48
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$27.6M, EPS −$0.58
- Quarter ended Sep 30, 2024: revenue n/a, net income −$27.9M, EPS −$0.58
- Quarter ended Jun 30, 2024: revenue n/a, net income $6.16M, EPS $0.13
- Quarter ended Mar 31, 2024: revenue n/a, net income $25.0M, EPS −$0.43
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$20.9M, EPS −$0.50
- Quarter ended Sep 30, 2023: revenue n/a, net income −$25.7M, EPS −$0.61
- Quarter ended Jun 30, 2023: revenue n/a, net income −$26.4M, EPS −$0.63
- Quarter ended Mar 31, 2023: revenue n/a, net income −$24.3M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$19.1M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$20.3M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$19.3M, EPS −$0.48
- Quarter ended Mar 31, 2022: revenue n/a, net income −$17.5M, EPS −$0.44
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$14.2M, EPS −$0.36
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.56M, EPS −$0.24
FLNA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$32.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$117M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$82.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$77.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$30.2M, share buybacks n/a
FLNA balance sheet
- Jun 30, 2026: cash $82.7M, total assets $104M, total liabilities $40.3M, shareholders' equity $63.6M
- Mar 31, 2026: cash $86.6M, total assets $108M, total liabilities $40.2M, shareholders' equity $68.1M
- Dec 31, 2025: cash $95.5M, total assets $118M, total liabilities $44.0M, shareholders' equity $74.4M
- Sep 30, 2025: cash $106M, total assets $130M, total liabilities $48.2M, shareholders' equity $81.6M
- Jun 30, 2025: cash $112M, total assets $135M, total liabilities $47.4M, shareholders' equity $88.0M
- Mar 31, 2025: cash $117M, total assets $141M, total liabilities $13.3M, shareholders' equity $128M
- Dec 31, 2024: cash $129M, total assets $158M, total liabilities $11.8M, shareholders' equity $146M
- Sep 30, 2024: cash $149M, total assets $224M, total liabilities $57.1M, shareholders' equity $167M
Is FLNA profitable?
No. FILANA THERAPEUTICS INC lost $42.3M over the last four quarters.